Moderna stock surges as melanoma vaccine trial shows "landmark moment"
Moderna and Merck announced study results that reflect a "landmark moment" in treatment for one of the deadliest forms of skin cancer.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cbsnews.com — the content belongs to CBS MoneyWatch.